Adapalene

Adapalene is a third-generation topical retinoid, meaning it is a synthetic compound that mimics the activity of vitamin A derivatives while being chemically more stable and better tolerated than earlier agents such as tretinoin ^[1][2]. Structurally it is a naphthoic acid derivative rather than a true retinoid, a design that gives it resistance to light and oxidation along with a selective pattern of receptor binding ^[2][3]. It is classed among the retinoid-like dermatological agents and is used almost entirely on the skin ^[3].

Developed as a receptor-selective retinoid, adapalene entered dermatology as a first-line topical treatment for mild to moderate acne, where it reduces both the clogged pores and the inflamed lesions that characterize the disease ^[1][4]. Numerous clinical studies established that it matches older topical retinoids such as tretinoin in effectiveness while causing less redness, dryness, and irritation, which improves the chance that people keep using it ^[1][3]. Its favorable tolerability made it a common part of combination acne regimens, often paired with antimicrobial agents ^[3].

Adapalene works by binding to specific nuclear retinoic acid receptors, chiefly the beta and gamma subtypes, thereby influencing genes that govern how skin cells mature and shed, and it also exerts anti-inflammatory effects ^[2][4]. It is supplied as gels, creams, and lotions in various strengths, and in some regions the lower-strength gel is sold without a prescription. In 2016, regulators in the United States approved an adapalene gel for over-the-counter sale, the first time a retinoid previously limited to prescription became directly available to consumers ^[1]. Elsewhere it commonly remains a prescription medicine, marketed under the name Differin among others ^[1].

Adapalene is available over the counter at 0.1 percent and by prescription at higher strengths. The main effects are local; dryness, redness, peeling, and stinging are common in the first few weeks as skin adjusts, a phase often called retinization. It can make skin more sensitive to sun, so daytime sunscreen matters. Systemic absorption is very low, but oral retinoids are strongly linked to birth defects, so as a precaution topical retinoids are generally avoided in pregnancy. Starting every other night and using a plain moisturizer eases the early irritation.

Adapalene should be avoided in combination with topical dapsone because both compounds are arylamines capable of inducing methemoglobinemia. A clinical case documented a 40-year-old patient who developed persistent methemoglobinemia with marked saturation gaps and elevated methaemoglobin levels (measured via co-oximetry) from unsupervised concurrent use of topical dapsone and adapalene; despite treatment with methylene blue, methaemoglobin levels repeatedly rebounded ^[6]. The risk appears to be cumulative when oxidizing agents or other methemoglobinemia-inducing topical agents are applied simultaneously.

Checking a whole stack? Run it through interactions + stacks.

Adapalene was developed by the dermatology company Galderma and introduced in the 1990s as a third-generation topical retinoid, receiving United States approval under the brand name Differin in 1996. Chemically it is a stable naphthoic acid derivative, a design intended to retain the acne-fighting activity of retinoic acid while resisting the light and oxygen degradation that limited earlier retinoids such as tretinoin. Its receptor selectivity for the beta and gamma subtypes of the retinoic acid receptor was characterized in foundational pharmacology work that distinguished it from naturally occurring retinoic acid. In 2016 the 0.1% gel became the first topical retinoid approved for over-the-counter sale for acne in the United States, a milestone that greatly expanded public access to prescription-grade retinoid therapy.

Adapalene enjoys a strong and durable reputation among dermatologists as a first-line topical treatment for acne, frequently cited for offering retinoid efficacy with comparatively good tolerability. It is often the retinoid clinicians reach for first in patients prone to irritation, since its chemical stability and receptor selectivity are associated with a gentler profile than older agents. Its move to over-the-counter status is widely viewed as a public-health win, putting an evidence-backed acne treatment within reach without a prescription. Users should still expect an adjustment period of dryness or mild irritation and understand that retinoids work gradually over weeks; realistic expectations, sun protection, and consistent nightly use are the keys most reviewers emphasize.